109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
低氧和失巢凋亡相关长链非编码 RNA 特征可定义肝细胞癌的分子亚型，并预测其预后及免疫治疗反应
Authors Lu X , Wang Y, Yu Y, Zhang R, Long F, Li M, Pan M, Du K, Tan J, He J, Li Z , Lin H, Li M
Received 7 April 2025
Accepted for publication 15 August 2025
Published 13 October 2025 Volume 2025:12 Pages 2307—2325
DOI https://doi.org/10.2147/JHC.S521878
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Prof. Dr. Imam Waked
Xiaohang Lu,1– 3,* Yunyong Wang,1,3,* Yuan Yu,4 Rongzhen Zhang,5 Fuli Long,5 Minpeng Li,4 Meng Pan,4 Kewei Du,6 Jinna Tan,1,3 Jiaqian He,1,3 Zongxian Li,7,8 Hongsheng Lin,1,6,* Mingfen Li1,6,*
1The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, 530023, People’s Republic of China; 2Department of Ophthalmology, The People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530016, People’s Republic of China; 3Guangxi Key Laboratory of Molecular Biology of Preventive Medicine of Traditional Chinese Medicine, Nanning, 530023, People’s Republic of China; 4Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, 530023, People’s Republic of China; 5Department of Hepatology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, 530023, People’s Republic of China; 6Laboratory Department, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, 530023, People’s Republic of China; 7Department of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530020, People’s Republic of China; 8Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of Education, Nanning, 530020, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Mingfen Li, Laboratory Department, The First Affiliated Hospital of Guangxi University of Chinese Medicine, No. 89-9 Dongge Road, Qingxiu District, Nanning, Guangxi Zhuang Autonomous Region, People’s Republic of China, Email limf@gxtcmu.edu.cn Hongsheng Lin, Laboratory Department, The First Affiliated Hospital of Guangxi University of Chinese Medicine, No. 89-9 Dongge Road, Qingxiu District, Nanning, Guangxi Zhuang Autonomous Region, People’s Republic of China, Email linhs@gxtcmu.edu.cn
Background: Hepatocellular carcinoma (HCC) is characterized by high incidence and mortality rates, with hypoxia and anoikis resistance playing crucial roles in its progression and metastasis. While long non-coding RNA (lncRNA) significantly influence tumor biology, their roles in hypoxia-anoikis-resistant HCC remain unclear.
Methods: This study utilized RNA-seq data and clinical information from the TCGA and GEO databases to analyze 154 hypoxia- and anoikis-related lncRNAs and identify differentially expressed candidates. Cluster analysis with Consensus Cluster Plus revealed links to clinical outcomes and genomic features. Tumor immune microenvironment and pathway enrichment were assessed using CIBERSORT and ssGSEA. A nine-gene risk model was developed via LASSO Cox regression and internally validated. Preliminary experimental assays suggested that the identified lncRNAs may influence apoptosis under hypoxia and anoikis conditions.
Results: HCC patients were classified into two molecular subtypes, C1 and C2, with distinct prognostic outcomes and clinical features. These subtypes showed distinct immune infiltration characteristics and differential immunotherapy response scores. A nine-lncRNA prognostic model effectively predicted overall survival (OS), with the high-risk group showing increased immunosuppressive elements, such as Tregs and inactivated M0 macrophages, suggesting limited immunotherapy efficacy. Chemotherapy sensitivity analysis revealed varying drug responses between risk groups, while hypoxia- and anoikis-related lncRNAs, including LINC01554, FIRRE, LINC01139, LINC01134 and NBAT1 were downregulated in this model.
Conclusion: Research has demonstrated that hypoxia- and anoikis-related lncRNAs serve as reliable biomarkers for predicting liver cancer prognosis and immunotherapy response, offering potential for developing novel therapeutic targets and strategies to enhance treatment outcomes and patient prognosis.
Keywords: hepatocellular carcinoma, anoikis, hypoxia, LncRNA, molecular subtypes
1The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, 530023, People’s Republic of China; 2Department of Ophthalmology, The People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530016, People’s Republic of China; 3Guangxi Key Laboratory of Molecular Biology of Preventive Medicine of Traditional Chinese Medicine, Nanning, 530023, People’s Republic of China; 4Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, 530023, People’s Republic of China; 5Department of Hepatology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, 530023, People’s Republic of China; 6Laboratory Department, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, 530023, People’s Republic of China; 7Department of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530020, People’s Republic of China; 8Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of Education, Nanning, 530020, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Mingfen Li, Laboratory Department, The First Affiliated Hospital of Guangxi University of Chinese Medicine, No. 89-9 Dongge Road, Qingxiu District, Nanning, Guangxi Zhuang Autonomous Region, People’s Republic of China, Email limf@gxtcmu.edu.cn Hongsheng Lin, Laboratory Department, The First Affiliated Hospital of Guangxi University of Chinese Medicine, No. 89-9 Dongge Road, Qingxiu District, Nanning, Guangxi Zhuang Autonomous Region, People’s Republic of China, Email linhs@gxtcmu.edu.cn
Background: Hepatocellular carcinoma (HCC) is characterized by high incidence and mortality rates, with hypoxia and anoikis resistance playing crucial roles in its progression and metastasis. While long non-coding RNA (lncRNA) significantly influence tumor biology, their roles in hypoxia-anoikis-resistant HCC remain unclear.
Methods: This study utilized RNA-seq data and clinical information from the TCGA and GEO databases to analyze 154 hypoxia- and anoikis-related lncRNAs and identify differentially expressed candidates. Cluster analysis with Consensus Cluster Plus revealed links to clinical outcomes and genomic features. Tumor immune microenvironment and pathway enrichment were assessed using CIBERSORT and ssGSEA. A nine-gene risk model was developed via LASSO Cox regression and internally validated. Preliminary experimental assays suggested that the identified lncRNAs may influence apoptosis under hypoxia and anoikis conditions.
Results: HCC patients were classified into two molecular subtypes, C1 and C2, with distinct prognostic outcomes and clinical features. These subtypes showed distinct immune infiltration characteristics and differential immunotherapy response scores. A nine-lncRNA prognostic model effectively predicted overall survival (OS), with the high-risk group showing increased immunosuppressive elements, such as Tregs and inactivated M0 macrophages, suggesting limited immunotherapy efficacy. Chemotherapy sensitivity analysis revealed varying drug responses between risk groups, while hypoxia- and anoikis-related lncRNAs, including LINC01554, FIRRE, LINC01139, LINC01134 and NBAT1 were downregulated in this model.
Conclusion: Research has demonstrated that hypoxia- and anoikis-related lncRNAs serve as reliable biomarkers for predicting liver cancer prognosis and immunotherapy response, offering potential for developing novel therapeutic targets and strategies to enhance treatment outcomes and patient prognosis.
Keywords: hepatocellular carcinoma, anoikis, hypoxia, LncRNA, molecular subtypes